In comparation with other pathologies, poor results are being achieved in clinical trials in Alzheimer ́s Disease. Last approved drugs by regulatory agencies, FDA and EMA, were accomplished in 2003 and 2002, respectively. By mid 2017, there were 105 molecules/ compounds/ candidates in the AD treatment development pipeline, of which 25 are in 29 phase I trials, 52 are in 68 phase II trials, and 28 are in 42 phase III trials (Cummings et al, Alzheimers Dement 2017). The lack of clinical correlate could be the main reason of this attrition rate in AD so a de-risking methodology is implemented for all the EoI in relation to AD received, focusing on target validation and companion biomarker incorporation.
This website uses cookies so that we can offer you the best possible user experience. The cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team to understand which sections of the website you find most interesting and useful.